Navigation Links
Stroke Study Reveals a Key Target For Improving Treatment
Date:6/22/2008

which is to break down clots that have lodged in the brain's blood vessels, cutting off blood supply to the area and starving brain tissue until it begins to die.

Such clots cause 80 percent of the 15 million strokes that occur each year worldwide. Five million people die, and 5 million more are permanently disabled, by strokes each year, according to the World Health Organization.

"Our findings may have immediate clinical relevance, and could be applied to find new treatments that will benefit stroke patients," says senior author Daniel Lawrence, Ph.D., professor of cardiovascular medicine in the U-M Medical School and member of the U-M Cardiovascular Center. "By better understanding how the brain regulates the permeability of the blood-brain barrier, and how tPA acts upon that system, we hope to reduce the risks and increase the time window for stroke treatment."

Ulf Eriksson, Ph.D., the leader of the team at the Ludwig Institute for Cancer Research Stockholm Branch at Karolinska Institutet, comments, "Our research group identified the growth factor PDGF-CC ten years ago and we are now very excited having unraveled a mechanism in the brain involving this factor, which potentially will be a revolution in the treatment of stroke. Together with our clinical colleagues at the Karolinska University Hospital in Stockholm we are now rapidly continuing to explore this exciting possibility in clinical trials involving stroke patients."

Eriksson and Lawrence collaborated with a number of colleagues -- including lead author Enming Joe Su, Ph.D. of U-M and teams at Karolinska Institutet, the University of Maryland and Emory University -- to perform the study.

Some of the mice in the study lacked the natural tPA that the body makes on its own. Some of the mice underwent a procedure that simulated the effects of a clot-based, or ischemic, stroke.

The researchers first demonstrated in non-stroke mice that tPA and PDGF-CC appeared to act
'/>"/>

SOURCE University of Michigan Health System
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
2. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
3. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
4. FASgen Announces New Discovery for Treatment of Stroke
5. ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ischemic Stroke
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
8. PRoFESS(R) Results Announced at XVII European Stroke Conference
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "MEMS Gyroscopes Analog Devices ADIS16136 Precision ... to their offering. ... grade applications made a lot of progress in ... They are now accepted in high-reliability environments, and ...
(Date:12/15/2014)... 2014 BerGenBio AS, a biopharmaceutical ... resistant cancers, today announces that it has raised NOK90 ... new and existing investors. BerGenBio will use ... of its pipeline of innovative cancer therapeutics, in particular ... candidate, BGB324, a first-in-class selective Axl kinase inhibitor, which ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2BerGenBio Completes NOK90 Million Fundraising 2
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced ... of Directors.  Dr. McKinnell is the former Chief Executive ... of Pfizer Inc.  He is currently Chairman of the ... infectious diseases in Africa, and is a member of ...
... and NEW YORK, Jan. 10, 2011 Resolvyx Pharmaceuticals ... Celtic Therapeutics ), a successor firm to Celtic Pharma, ... agreement under which Celtic Therapeutics has acquired and licensed ... for the treatment of dry eye syndrome and other ...
Cached Medicine Technology:Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors 2Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors 3Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors 4Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 2Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 3Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 4
(Date:12/17/2014)... parents should leave prenatal picture-taking to medical professionals, the ... ultrasound imaging and heartbeat monitors to get "keepsake" images ... "Although there is a lack of evidence ... monitors, prudent use of these devices by trained health ... engineer, said in an agency news release. "Ultrasound ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 ... overall health, but a growing body of evidence shows the ... finds. In fact, the benefits were similar to those ... Paula Chu, a doctoral candidate at Harvard University,s Health Policy ... found that people randomly assigned to take yoga classes saw ...
(Date:12/15/2014)... 2014 Veretekk.com, Inc. announced today a ... JM Ocean Avenue has secured exclusive benefit to ... marketing system. JM Ocean Avenue is a direct ... Ocean Avenue and JM International, with partial ownership coming ... year company. , “After nearly 2 decades of servicing ...
(Date:12/15/2014)... 2014 OutMarket , a provider ... Social Media Cheat Sheets ,” a guide that exposes ... results on the top ten social media networks. ... drive awareness, engagement, and customer service. It can also ... an impact on new networks and weather constantly changing ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss in the ... contributing to the growth in the global audiological market. Devices ... loss and balance disorders are known as audiological devices. An ... amplifier. The global market is expected to grow at a ... 2014 to 2019. Some of the factors which are driving ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... recent tests conducted by the Analytical Services Tasmania King Island's ... Greens conducted tests which showed high content of lead in ... by testing done by the council which found no problem ... heavy metals and the results were announced with days of ...
... by the investigators at John Hopkins Children’s Center//, patient’s safety ... the medication errors into a computer database. ... fixing and reporting on the errors voluntarily plus steps taken ... systems are not new, but few studies have looked at ...
... the end of last year, surgeons from Australia had performed ... Royal Prince Alfred Hospital had carried out the surgery on ... South Wales. Leanne Myles was reported to be on her ... pancreas. ,She was diagnosed when she was 19, ...
... held at Varca in Goa it is found that ... levels. //The two day conference mainly analyzed the ... to hyperhomocysteinemia. This would further worsen the situation by ... heart attack, diabetes and other fatal diseases. Experts and ...
... education to youngsters is important to tackle HIV/AIDS in ... // ,Engaging youngsters and giving them leadership ... necessary, Micheal Friedman of Centre for Disease Control of ... Madras Medical Mission., ,Clinical commitment, expertise in treatment ...
... United Nations has sounded alarm over rising cocaine consumption ... rise again in Afghanistan this year reversing the decline ... report, the world body urged European Union governments not ... use cocaine, often denying their addiction, and drug abuse ...
Cached Medicine News:Health News:Voluntary Error-Reporting System Ensures Patient Safety 2Health News:Voluntary Error-Reporting System Ensures Patient Safety 3Health News:Voluntary Error-Reporting System Ensures Patient Safety 4
CUSA DISSECTRON PORTABLE UNIT is an ultrasonic surgical aspirator for the fragmentation and emulsification of tissue available only outside the United States....
The Nevyas Drape Support is the simple and inexpensive way to establish a zone of comfort for your patients during ophthalmic surgery which requires draping over the nose and mouth. Packaged in sets ...
This is a 2.5x focusing Galilean telescope with a range from 70cm to infinity. Ideal for use at sporting events, as well as for a wide range of hobbies....
... Hi-Mag takes us to the practical ... magnifier is often a 'last resort' ... visual acuities. The illuminated housing ensures ... to the battery handle by a ...
Medicine Products: